✦ LIBER ✦

Experimental drug shows promise for elderly chronic leukemia patients

✍ Scribed by Mohindru, Pooja; Khanna, Rajesh; Bhatia, S. S.

Book ID: 118305480
Publisher: Springer-Verlag
Year: 2012
Weight: 77 KB
Volume: 1
Category: Article
ISSN: 2193-0961
DOI: 10.1007/s40014-012-0342-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tyrosine kinase inhibitors for elderly c

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data

✍ Massimo Breccia; Mario Tiribelli; Giuliana Alimena 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 275 KB

DU6 ASSESSMENT OF DRUG UTILIZATION PATTE

DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

✍ MH Lafeuille; P Lefebvre; B Bookhart; F Laliberte; R Bailey; M Corral; CT Piech 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Long-term safety and efficacy of imatini

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

✍ Philippe Rousselot; Pascale Cony-Makhoul; Franck Nicolini; François Xavier Mahon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

First-line therapy with fludarabine comp

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

✍ Eichhorst, B. F.; Busch, R.; Stilgenbauer, S.; Stauch, M.; Bergmann, M. A.; Ritg 📂 Article 📅 2009 🏛 American Society of Hematology 🌐 English ⚖ 324 KB

Safe switching from dasatinib to nilotin

Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase

✍ Yasunobu Nagata; Shiomi Fukuda; Takeshi Kobayashi; Takuya Yamashita; Kazuteru Oh 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 207 KB

Results of the MRC pilot study show auto

Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses

✍ Milligan, D. W. 📂 Article 📅 2005 🏛 American Society of Hematology 🌐 English ⚖ 287 KB